المؤلفون: Laurene, Ben Aim, Eamonn R, Maher, Alberto, Cascon, Anne, Barlier, Sophie, Giraud, Tonino, Ercolino, Pascal, Pigny, Roderick J, Clifton-Bligh, Delphine, Mirebeau-Prunier, Amira, Mohamed, Judith, Favier, Anne-Paule, Gimenez-Roqueplo, Francesca, Schiavi, Rodrigo A, Toledo, Patricia L, Dahia, Mercedes, Robledo, Jean Pierre, Bayley, Nelly, Burnichon

المصدر: Journal of medical genetics. 59(8)

مصطلحات موضوعية: Paraganglioma, Succinate Dehydrogenase, Adrenal Gland Neoplasms, Humans, Genetic Testing, Pheochromocytoma, Germ-Line Mutation

الوصف: A total of 223 distinctThis multistep process resulted in 23 benign/likely benign, 149 pathogenic/likely pathogenic variants and 51 variants of unknown significance (VUS). Expert curation reduced by half the number of variants initially classified as VUS. Variant classifications are publicly accessible via the Leiden Open Variation Database system (https://databases.lovd.nl/shared/genes/SDHB).This international initiative by a panel of experts allowed us to establish a consensus classification for 223

URL الوصول: https://explore.openaire.eu/search/publication?articleId=pmid________::6d919922d0db87f10b9c47ca9a99899b
https://pubmed.ncbi.nlm.nih.gov/34452955

المؤلفون: Emilia M. Swietlik, Daniel Greene, Na Zhu, Karyn Megy, Marcella Cogliano, Smitha Rajaram, Divya Pandya, Tobias Tilly, Katie A. Lutz, Carrie C.L. Welch, Michael W. Pauciulo, Laura Southgate, Jennifer M. Martin, Carmen M. Treacy, Christopher J. Penkett, Jonathan C. Stephens, Harm J. Bogaard, Colin Church, Gerry Coghlan, Anna W. Coleman, Robin Condliffe, Christina A. Eichstaedt, Mélanie Eyries, Henning Gall, Stefano Ghio, Barbara Girerd, Ekkehard Grünig, Simon Holden, Luke Howard, Marc Humbert, David G. Kiely, Gabor Kovacs, Jim Lordan, Rajiv D. Machado, Robert V. MacKenzie Ross, Colm McCabe, Shahin Moledina, David Montani, Horst Olschewski, Joanna Pepke-Zaba, Laura Price, Christopher J. Rhodes, Werner Seeger, Florent Soubrier, Jay Suntharalingam, Mark R. Toshner, Anton Vonk Noordegraaf, John Wharton, James M. Wild, Stephen John Wort, Allan Lawrie, Martin R. Wilkins, Richard C. Trembath, Yufeng Shen, Wendy K. Chung, Andrew J. Swift, William C. Nichols, Nicholas W. Morrell, Stefan Gräf, Stephen Abbs, Lara Abulhoul, Julian Adlard, Munaza Ahmed, Timothy J. Aitman, Hana Alachkar, David J. Allsup, Philip Ancliff, Richard Antrobus, Ruth Armstrong, Gavin Arno, Sofie Ashford, William J. Astle, Anthony Attwood, Paul Aurora, Christian Babbs, Chiara Bacchelli, Tamam Bakchoul, Siddharth Banka, Tadbir Bariana, Julian Barwell, Joana Batista, Helen E. Baxendale, Phil L. Beales, David L. Bennett, Agnieszka Bierzynska, Tina Biss, Maria A.K. Bitner-Glindzicz, Graeme C. Black, Marta Bleda, Iulia Blesneac, Detlef Bockenhauer, Sara Boyce, John R. Bradley, Gerome Breen, Paul Brennan, Carole Brewer, Matthew Brown, Andrew C. Browning, Michael J. Browning, Rachel J. Buchan, Matthew S. Buckland, Teofila Bueser, Carmen Bugarin Diz, John Burn, Siobhan O. Burns, Oliver S. Burren, Nigel Burrows, Carolyn Campbell, Gerald Carr-White, Keren Carss, Ruth Casey, Mark J. Caulfield, Jenny Chambers, John Chambers, Melanie M.Y. Chan, Floria Cheng, Patrick F. Chinnery, Manali Chitre, Martin T. Christian, Jill Clayton-Smith, Maureen Cleary, Naomi Clements Brod, Elizabeth Colby, Trevor R.P. Cole, Janine Collins, Peter W. Collins, Cecilia J. Compton, H. Terence Cook, Stuart Cook, Nichola Cooper, Paul A. Corris, Nicola S. Curry, Matthew J. Daniels, Mehul Dattani, Louise C. Daugherty, John Davis, Anthony De Soyza, Sri V.V. Deevi, Timothy Dent, Charu Deshpande, Eleanor F. Dewhurst, Peter H. Dixon, Sofia Douzgou, Kate Downes, Anna M. Drazyk, Elizabeth Drewe, Daniel Duarte, Tina Dutt, J. David M. Edgar, Karen Edwards, William Egner, Melanie N. Ekani, Perry Elliott, Wendy N. Erber, Marie Erwood, Maria C. Estiu, Dafydd Gareth Evans, Gillian Evans, Tamara Everington, Hiva Fassihi, Remi Favier, Debra Fletcher, Frances A. Flinter, R. Andres Floto, Tom Fowler, James Fox, Amy J. Frary, Courtney E. French, Kathleen Freson, Mattia Frontini, Abigail Furnell, Daniel P. Gale, Vijeya Ganesan, Michael Gattens, Hossein-Ardeschir Ghofrani, J. Simon R. Gibbs, Kate Gibson, Kimberly C. Gilmour, Nicholas S. Gleadall, Sarah Goddard, Keith Gomez, Pavels Gordins, David Gosal, Jodie Graham, Luigi Grassi, Lynn Greenhalgh, Andreas Greinacher, Paolo Gresele, Philip Griffiths, Sofia Grigoriadou, Detelina Grozeva, Mark Gurnell, Scott Hackett, Charaka Hadinnapola, Rosie Hague, William M. Hague, Matthias Haimel, Matthew Hall, Helen L. Hanson, Eshika Haque, Kirsty Harkness, Andrew R. Harper, Claire L. Harris, Daniel Hart, Ahamad Hassan, Grant Hayman, Alex Henderson, Archana Herwadkar, Jonathan Hoffman, Rita Horvath, Henry Houlden, Arjan C. Houweling, Fengyuan Hu, Gavin Hudson, Aarnoud P. Huissoon, Matthew Hurles, Melita Irving, Louise Izatt, Roger James, Sally A. Johnson, Stephen Jolles, Jennifer Jolley, Dragana Josifova, Neringa Jurkute, Mary A. Kasanicki, Hanadi Kazkaz, Rashid Kazmi, Peter Kelleher, Anne M Kelly, Wilf Kelsall, Carly Kempster, Nathalie Kingston, Nils Koelling, Myrto Kostadima, Ania Koziell, Roman Kreuzhuber, Taco W. Kuijpers, Ajith Kumar, Dinakantha Kumararatne, Manju A. Kurian, Michael A. Laffan, Fiona Lalloo, Michele Lambert, Hana Lango Allen, D. Mark Layton, Claire Lentaigne, Tracy Lester, Adam P. Levine, Rachel Linger, Hilary Longhurst, Lorena E. Lorenzo, Eleni Louka, Paul A. Lyons, Bella Madan, Eamonn R. Maher, Jesmeen Maimaris, Samantha Malka, Sarah Mangles, Rutendo Mapeta, Kevin J. Marchbank, Stephen Marks, Hugh S. Markus, Hanns-Ulrich Marschall, Andrew Marshall, Mary Mathias, Emma Matthews, Heather Maxwell, Paul McAlinden, Mark I. McCarthy, Harriet McKinney, Stuart Meacham, Adam J. Mead, Sarju G. Mehta, Michel Michaelides, Carolyn Millar, Shehla N. Mohammed, Anthony T. Moore, Monika Mozere, Keith W. Muir, Andrew D. Mumford, Andrea H. Nemeth, William G. Newman, Michael Newnham, Sadia Noorani, Paquita Nurden, Jennifer O’Sullivan, Samya Obaji, Chris Odhams, Steven Okoli, Andrea Olschewski, Kai Ren Ong, S. Helen Oram, Elizabeth Ormondroyd, Willem H. Ouwehand, Claire Palles, Sofia Papadia, Soo-Mi Park, David Parry, Smita Patel, Joan Paterson, Andrew Peacock, Simon H. Pearce, Kathelijne Peerlinck, Romina Petersen, Clarissa Pilkington, Kenneth E.S. Poole, Bethan Psaila, Angela Pyle, Richard Quinton, Shamima Rahman, Anupama Rao, F. Lucy Raymond, Paula J. Rayner-Matthews, Augusto Rendon, Tara Renton, Andrew S.C. Rice, Alex Richter, Leema Robert, Irene Roberts, Sarah J. Rose, Robert Ross-Russell, Catherine Roughley, Noemi B.A. Roy, Deborah M. Ruddy, Omid Sadeghi-Alavijeh, Moin A. Saleem, Nilesh Samani, Crina Samarghitean, Alba Sanchis-Juan, Ravishankar B. Sargur, Robert N. Sarkany, Simon Satchell, Sinisa Savic, Genevieve Sayer, John A. Sayer, Laura Scelsi, Andrew M. Schaefer, Sol Schulman, Richard Scott, Marie Scully, Claire Searle, Arjune Sen, W.A. Carrock Sewell, Denis Seyres, Neil Shah, Olga Shamardina, Susan E. Shapiro, Adam C. Shaw, Keith Sibson, Lucy Side, Ilenia Simeoni, Michael A. Simpson, Matthew C. Sims, Suthesh Sivapalaratnam, Damian Smedley, Katherine R. Smith, Kenneth G.C. Smith, Katie Snape, Nicole Soranzo, Olivera Spasic-Boskovic, Simon Staines, Emily Staples, Hannah Stark, Kathleen E. Stirrups, Alex Stuckey, Petros Syrris, R. Campbell Tait, Kate Talks, Rhea Y.Y. Tan, Jenny C. Taylor, John M. Taylor, James E. Thaventhiran, Andreas C. Themistocleous, David Thomas, Ellen Thomas, Moira J. Thomas, Patrick Thomas, Kate Thomson, Adrian J. Thrasher, Chantal Thys, Marc Tischkowitz, Catherine Titterton, Cheng-Hock Toh, Ian P. Tomlinson, Matthew Traylor, Paul Treadaway, Salih Tuna, Ernest Turro, Philip Twiss, Tom Vale, Chris Van Geet, Natalie van Zuydam, Anthony M Vandersteen, Marta Vazquez-Lopez, Julie von Ziegenweidt, Annette Wagner, Quinten Waisfisz, Neil Walker, Suellen M. Walker, James S. Ware, Hugh Watkins, Christopher Watt, Andrew R. Webster, Lucy Wedderburn, Wei Wei, Steven B. Welch, Julie Wessels, Sarah K. Westbury, John-Paul Westwood, Deborah Whitehorn, James Whitworth, Andrew O.M. Wilkie, Catherine Williamson, Brian T. Wilson, Edwin K.S. Wong, Nicholas Wood, Yvette Wood, Christopher Geoffrey Woods, Emma R. Woodward, Austen Worth, Michael Wright, Katherine Yates, Patrick F.K. Yong, Timothy Young, Ping Yu, Patrick Yu-Wai-Man, Eliska Zlamalova, Russel Hirsch, R. James White, Marc Simon, David Badesch, Erika Rosenzweig, Charles Burger, Murali Chakinala, Thenappan Thenappan, Greg Elliott, Robert Simms, Harrison Farber, Robert Frantz, Jean Elwing, Nicholas Hill, Dunbar Ivy, James Klinger, Steven Nathan, Ronald Oudiz, Ivan Robbins, Robert Schilz, Terry Fortin, Jeffrey Wilt, Delphine Yung, Eric Austin, Ferhaan Ahmad, Nitin Bhatt, Tim Lahm, Adaani Frost, Zeenat Safdar, Zia Rehman, Robert Walter, Fernando Torres, Sahil Bakshi, Stephen Archer, Rahul Argula, Christopher Barnett, Raymond Benza, Ankit Desai, Veeranna Maddipati

المساهمون: University of Cambridge [UK] (CAM), Columbia University [New York], University of Sheffield [Sheffield], University of Cincinnati (UC), St George's, University of London, Vrije Universiteit Amsterdam [Amsterdam] (VU), Golden Jubilee National Hospital, Glasgow, Royal Free Hospital [London, UK], Heidelberg University Hospital [Heidelberg], Service de Génétique Cytogénétique et Embryologie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Technische Hochschule Mittelhessen - University of Applied Sciences [Giessen] (THM), Fondazione IRCCS Policlinico San Matteo, Hypertension pulmonaire : physiopathologie et innovation thérapeutique (HPPIT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Universität Heidelberg [Heidelberg], Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Imperial College London, Royal Hallamshire Hospital, University of Graz, Freeman Hospital, Royal United Hospitals Bath (RUH), Great Ormond Street Hospital for Children [London] (GOSH), Royal Papworth Hospital, Cambridge Biomedical Campus, Cambridge, United Kingdom., King‘s College London, Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Karl-Franzens-Universität [Graz, Autriche], Pulmonary medicine, ACS - Pulmonary hypertension & thrombosis, Swietlik, Emilia [0000-0002-4095-8489], Megy, Karyn [0000-0002-2826-3879], Tilly, Tobias [0000-0002-6762-5342], Stephens, Jonathan [0000-0003-2020-9330], Toshner, Mark [0000-0002-3969-6143], Morrell, Nicholas [0000-0001-5700-9792], Graf, Stefan [0000-0002-1315-8873], Apollo - University of Cambridge Repository, Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Karl-Franzens-Universität Graz, HAL-SU, Gestionnaire, British Heart Foundation, The Academy of Medical Sciences

المصدر: Circulation: Genomic and Precision Medicine
Circulation: Genomic and Precision Medicine, American Heart Association, 2020, ⟨10.1161/CIRCGEN.120.003155⟩
Circulation. Genomic and Precision Medicine
Circulation. Genomic and precision medicine, 14(1):e003155. Lippincott Williams and Wilkins Ltd.
morrell 2021, ' Bayesian Inference Associates Rare KDR Variants with Specific Phenotypes in Pulmonary Arterial Hypertension ', Circulation. Genomic and precision medicine, vol. 14, no. 1, e003155 . https://doi.org/10.1161/CIRCGEN.120.003155
Circulation: Genomic and Precision Medicine, 2020, ⟨10.1161/CIRCGEN.120.003155⟩

مصطلحات موضوعية: 0301 basic medicine, Candidate gene, Cardiac & Cardiovascular Systems, genetic association studies, 030204 cardiovascular system & hematology, Biology, Bayesian inference, 03 medical and health sciences, 0302 clinical medicine, Missing heritability problem, pulmonary hypertension, medicine, Family history, Gene, Genetics & Heredity, Genetics, family history, Science & Technology, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, Kinase insert domain receptor, computed tomography, General Medicine, Original Articles, medicine.disease, Pulmonary hypertension, Phenotype, 3. Good health, 030104 developmental biology, Cardiovascular System & Cardiology, ComputingMethodologies_DOCUMENTANDTEXTPROCESSING, Life Sciences & Biomedicine, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, vascular endothelial growth factor receptor

الوصف: Supplemental Digital Content is available in the text.
Background: Approximately 25% of patients with pulmonary arterial hypertension (PAH) have been found to harbor rare mutations in disease-causing genes. To identify missing heritability in PAH, we integrated deep phenotyping with whole-genome sequencing data using Bayesian statistics. Methods: We analyzed 13 037 participants enrolled in the NBR study (NIHR BioResource—Rare Diseases), of which 1148 were recruited to the PAH domain. To test for genetic associations between genes and selected phenotypes of pulmonary hypertension, we used the Bayesian rare variant association method BeviMed. Results: Heterozygous, high impact, likely loss-of-function variants in the kinase insert domain receptor (KDR) gene were strongly associated with significantly reduced transfer coefficient for carbon monoxide (posterior probability=0.989) and older age at diagnosis (posterior probability=0.912). We also provide evidence for familial segregation of a rare nonsense KDR variant with these phenotypes. On computed tomographic imaging of the lungs, a range of parenchymal abnormalities were observed in the 5 patients harboring these predicted deleterious variants in KDR. Four additional PAH cases with rare likely loss-of-function variants in KDR were independently identified in the US PAH Biobank cohort with similar phenotypic characteristics. Conclusions: The Bayesian inference approach allowed us to independently validate KDR, which encodes for the VEGFR2 (vascular endothelial growth factor receptor 2), as a novel PAH candidate gene. Furthermore, this approach specifically associated high impact likely loss-of-function variants in the genetically constrained gene with distinct phenotypes. These findings provide evidence for KDR being a clinically actionable PAH gene and further support the central role of the vascular endothelium in the pathobiology of PAH.

وصف الملف: application/pdf; application/vnd.openxmlformats-officedocument.wordprocessingml.document

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::524b66714d301fd180ea8d1d09ee8e86
https://hal.sorbonne-universite.fr/hal-03104099

المؤلفون: Diana Walsh, Graeme R. Clark, Ezequiel Martin, Neil V. Morgan, Louise Tee, Hannah Titheradge, Evan Reid, Mary O'Driscoll, Eamonn R. Maher, Bryndis Yngvadottir

المساهمون: Martin, Ezequiel [0000-0002-0051-8868], Reid, Evan [0000-0003-1623-7304], Maher, Eamonn R [0000-0002-6226-6918], Apollo - University of Cambridge Repository

المصدر: Brain Communications

مصطلحات موضوعية: 0301 basic medicine, Genetics, cerebral palsy, business.industry, General Engineering, autosomal recessive, medicine.disease, inherited, Cerebral palsy, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Spastic cerebral palsy, Genetic linkage, Paralysis, Spastic, Missense mutation, Medicine, Original Article, medicine.symptom, business, 030217 neurology & neurosurgery, Loss function, Exome sequencing

الوصف: A subset of individuals diagnosed with cerebral palsy will have an underlying genetic diagnosis. Previously, a missense variant in GAD1 was described as a candidate mutation in a single family diagnosed with autosomal recessive spastic cerebral palsy-1 (CPSQ1; OMIM 603513). Following the ascertainment of a further branch of the CPSQ1 kindred, we found that the previously reported GAD1 variant did not segregate with the neurological disease phenotype in the recently ascertained branch of the kindred. Following genetic linkage studies to map autozygous regions and whole-exome sequencing, a missense variant (c.527 T > C; p. Leu176Pro, rs773333490) in the HPDL gene was detected and found to segregate with disease status in both branches of the kindred. HPDL encodes a 371-amino acid protein (4-Hydroxyphenylpyruvate Dioxygenase Like) that localizes to mitochondria but whose function is uncertain. Recently, biallelic loss of function variants and missense substitution-causing variants in HPDL were reported to cause a childhood onset progressive spastic movement disorder with a variable presentation. These findings suggest that HPDL-related neurological disease may mimic spastic cerebral palsy and that GAD1 should not be included in diagnostic gene panels for inherited cerebral palsy.
Morgan et al. report that a novel candidate mutation in the HPDL gene (but not GAD1) segregates with disease status within a kindred in which a locus for autosomal recessive spastic cerebral palsy-1 (CPSQ1; OMIM 603513, GAD1) was mapped previously (in part of the kindred).
Graphical Abstract

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::963925c09b25fd4fb0d71debf31d4f84

المؤلفون: Lynn Rochester, John T. O'Brien, Joanna Knee, Alistair S. Hall, Paul Dark, Miles D. Witham, Laurie Oliva, Kim Down, Eleanor Anderson, Gary Nestor, James Wason, Camille Carroll, Rebecca Maier, Eamonn R. Maher, Gail Mountain

المساهمون: Witham, Miles D [0000-0002-1967-0990], Carroll, Camille B [0000-0001-7472-953X], Apollo - University of Cambridge Repository

المصدر: Witham, M D, Anderson, E, Carroll, C, Dark, P, Down, K, Hall, A S, Knee, J, Maher, E H, Maier, R H, Mountain, G A, Nestor, G, O'Brien, J T, Oliva, L, Watson, J & Rochester, L 2020, ' Ensuring that COVID-19 Research is Inclusive-guidance from the NIHR INCLUDE project ', BMJ Open . https://doi.org/10.1136/bmjopen-2020-043634
BMJ Open, Vol 10, Iss 11 (2020)
Witham, MD, Dark, PM, Down, K, Knee, J, Maher, ER, Maier, RH, Mountain, GA, Nestor, G, Oliva, L, Wason, J & Group, NIHR CRN INCLUDE S 2020, ' Ensuring that COVID-19 research is inclusive: guidance from the NIHR INCLUDE project. ', BMJ Open . https://doi.org/10.1136/bmjopen-2020-043634
BMJ Open

مصطلحات موضوعية: medicine.medical_specialty, Biomedical Research, Coronavirus disease 2019 (COVID-19), statistics & research methods, Psychological intervention, Ethnic group, Humans, Medicine, Minority Groups, Community engagement, SARS-CoV-2, business.industry, Public health, Clinical study design, public health, COVID-19, General Medicine, Public relations, Intervention (law), Identification (information), business, Research methods

الوصف: ObjectiveTo provide guidance to researchers, funders, regulators and study delivery teams to ensure that research on COVID-19 is inclusive, particularly of groups disproportionately affected by COVID-19 and who may have been historically under-served by research.Summary of key pointsGroups who are disproportionately affected by COVID-19 include (but are not limited to) older people, people with multiple long-term conditions, people with disabilities, people from Black, Asian and Ethnic minority groups, people living with obesity, people who are socioeconomically deprived and people living in care homes. All these groups are under-served by clinical research, and there is an urgent need to rectify this if COVID-19 research is to deliver relevant evidence for these groups who are most in need. We provide a framework and checklists for addressing key issues when designing and delivering inclusive COVID-19 research, based on the National Institute for Health Research INnovations in CLinical trial design and delivery for the UnDEr-served project roadmap. Strong community engagement, codevelopment and prioritisation of research questions and interventions are essential. Under-served groups should be represented on funding panels and ethics committees, who should insist on the removal of barriers to participation. Exclusion criteria should be kept to a minimum; intervention delivery and outcome measurement should be simple, flexible and tailored to the needs of different groups, and local advice on the best way to reach and engage with under-served communities should be taken by study delivery teams. Data on characteristics that allow identification of under-served groups must be collected, analyses should include these data to enable subgroup comparisons and results should be shared with under-served groups at an early stage.ConclusionInclusive COVID-19 research is a necessity, not a luxury, if research is to benefit all the communities it seeks to serve. It requires close engagement with under-served groups and attention to aspects of study topic, design, delivery, analysis and dissemination across the research life cycle.

وصف الملف: text/xml; application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e31b58ff21e22486465ad72e5a06990
https://research.manchester.ac.uk/en/publications/f0b7b393-08f9-4f4d-8250-9f2fcb0121c0

المؤلفون: Ruth T Casey, Hartmut P. H. Neumann, Eamonn R. Maher

المساهمون: Maher, Eamonn [0000-0002-6226-6918], Apollo - University of Cambridge Repository

المصدر: Hum Mol Genet

مصطلحات موضوعية: 0301 basic medicine, Evidence-based practice, Invited Review Article, Adrenal Gland Neoplasms, Pheochromocytoma, Biology, Bioinformatics, Paraganglioma, 03 medical and health sciences, 0302 clinical medicine, Genotype, Genetics, medicine, Humans, Genetic Testing, Precision Medicine, Molecular Biology, Genetics (clinical), Germ-Line Mutation, Genetic heterogeneity, General Medicine, Precision medicine, medicine.disease, Clinical Practice, Succinate Dehydrogenase, 030104 developmental biology, 030220 oncology & carcinogenesis, Signal Transduction

الوصف: Over the past two decades advances in genomic technologies have transformed knowledge of the genetic basis of phaeochromocytoma and paraganglioma (PPGL). Though traditional teaching suggested that inherited cases accounted for only 10% of all phaeochromocytoma diagnosis, current estimates are at least three times this proportion. Inherited PPGL is a highly genetically heterogeneous disorder but the most frequently results from inactivating variants in genes encoding subunits of succinate dehydrogenase. Expanding knowledge of the genetics of PPGL has been translated into clinical practice by the provision of widespread testing for inherited PPGL. In this review, we explore how the molecular stratification of PPGL is being utilized to enable more personalized strategies for investigation, surveillance and management of affected individuals and their families. Translating recent genetic research advances into clinical service can not only bring benefits through more accurate diagnosis and risk prediction but also challenges when there is a suboptimal evidence base for the clinical consequences or significance of rare genotypes. In such cases, clinical, biochemical, pathological and functional imaging assessments can all contribute to more accurate interpretation and clinical management.

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d7ea84a78c8bba740b3a03e9ba8e6cc
https://pubmed.ncbi.nlm.nih.gov/33059362

المؤلفون: Steven C Clifford, Matthew E Cockman, Alan C Smallwood, David R Mole, Emma R Woodward, Patrick H Maxwell, Peter J Ratcliffe, Eamonn R Maher

المصدر: Human Molecular Genetics. 30:844-845

مصطلحات موضوعية: Genetics, General Medicine, Molecular Biology, Genetics (clinical)

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::7c8c2b0345bf54d32d24aac00b83af2f
https://doi.org/10.1093/hmg/ddab037

المؤلفون: Venkata R. Bulusu, Philip Smith, James Whitworth, Basetti Madhu, Graeme R. Clark, Thomas Roberts, Alison Marker, Kieren Allinson, Ruth T Casey, Soo-Mi Park, Mel Maranian, Olivier Giger, Eguzkine Ochoa, Jose Ezequiel Martin, Colin Watts, Rogier ten Hoopen, Joanne Anstee, Fay Rodger, Eamonn R. Maher, Luis Miguel Pino Campos, Benjamin G. Challis

المساهمون: Madhu, Basetti [0000-0001-5844-856X], Campos, Luis [0000-0002-4317-0013], Maher, Eamonn R [0000-0002-6226-6918], Apollo - University of Cambridge Repository, Maher, Eamonn R. [0000-0002-6226-6918]

المصدر: Scientific Reports, Vol 9, Iss 1, Pp 1-10 (2019)
Scientific Reports

مصطلحات موضوعية: 0301 basic medicine, Epigenomics, Male, SDHA, Adrenal Gland Neoplasms, medicine.disease_cause, Germline, Epigenesis, Genetic, 0302 clinical medicine, Renal cell carcinoma, Paraganglioma, Genes, Regulator, Promoter Regions, Genetic, 45/90, Mutation, Multidisciplinary, Molecular medicine, GiST, article, High-Throughput Nucleotide Sequencing, Middle Aged, Succinate Dehydrogenase, Oncology, Medicine, Female, Adult, Adolescent, Gastrointestinal Stromal Tumors, Science, 45/22, 45/23, Pheochromocytoma, 692/4028, 03 medical and health sciences, medicine, Humans, Loss function, Germ-Line Mutation, Aged, 45/91, business.industry, Membrane Proteins, DNA Methylation, medicine.disease, 692/4017, 030104 developmental biology, Mutation testing, Cancer research, business, Transcriptome, 030217 neurology & neurosurgery

الوصف: The enzyme succinate dehydrogenase (SDH) functions in the citric acid cycle and loss of function predisposes to the development of phaeochromocytoma/paraganglioma (PPGL), wild type gastrointestinal stromal tumour (wtGIST) and renal cell carcinoma. SDH-deficient tumours are most commonly associated with a germline SDH subunit gene (SDHA/B/C/D) mutation but can also be associated with epigenetic silencing of the SDHC gene. However, clinical diagnostic testing for an SDHC epimutation is not widely available. The objective of this study was to investigate the indications for and the optimum diagnostic pathways for the detection of SDHC epimutations in clinical practice. SDHC promoter methylation analysis of 32 paraffin embedded tumours (including 15 GIST and 17 PPGL) was performed using a pyrosequencing technique and correlated with SDHC gene expression. SDHC promoter methylation was identified in 6 (18.7%) tumours. All 6 SDHC epimutation cases presented with SDH deficient wtGIST and 3/6 cases had multiple primary tumours. No case of constitutional SDHC promoter hypermethylation was detected. Whole genome sequencing of germline DNA from three wtGIST cases with an SDHC epimutation, did not reveal any causative sequence anomalies. Herein, we recommend a diagnostic workflow for the detection of an SDHC epimutation in a service setting.

وصف الملف: application/pdf; text/xml

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5941746c1b6527ac8d94245524e35a9c

المؤلفون: Zerin, Hyder, Adele, Fairclough, Mike, Groom, Joan, Getty, Elizabeth, Alexander, Elke M, van Veen, Guy, Makin, Chitra, Sethuraman, Vivian, Tang, D Gareth, Evans, Eamonn R, Maher, Emma R, Woodward

المصدر: Journal of medical genetics. 58(9)

مصطلحات موضوعية: Comparative Genomic Hybridization, DNA Copy Number Variations, Biopsy, Infant, Immunohistochemistry, Magnetic Resonance Imaging, Kidney Neoplasms, Repressor Proteins, Phenotype, Cytogenetic Analysis, Humans, Female, Genetic Predisposition to Disease, Genetic Association Studies, Germ-Line Mutation, In Situ Hybridization, Fluorescence, Sequence Deletion

الوصف: Nephroblastomatosis is a recognised precursor for the development of Wilms tumour (WT), the most common childhood renal tumour. While the majority of WT is sporadic in origin, germline intragenic mutations of predisposition genes such asTo highlight the role of a constitutional deletion CNV (delCNV) encompassing theArray comparative genomic hybridisation in an infant presenting with apparently sporadic diffuse HPLN revealed a de novo germline CNV, arr[GRCh37] 4q12(57,385,330-57,947,405)x1. TheThis delCNV encompassing

URL الوصول: https://explore.openaire.eu/search/publication?articleId=pmid________::e7cf45d9c8af67f5c897ae8bc771296d
https://pubmed.ncbi.nlm.nih.gov/32917767

المؤلفون: Finlay A. Macrae, Toni T. Seppälä, Gillian M. Borthwick, Anne-Marie Gerdes, D. Gareth Evans, Fiona E McRonald, Lynn Reed, Huw Thomas, Julian R. Sampson, Jackie Cook, Shirley Hodgson, Mary Porteous, Jukka-Pekka Mecklin, Lucy Side, Anthony Ellis, John Burn, Carole Brewer, Lucio Bertario, Kirsi Pylvänäinen, D. Timothy Bishop, Diana Eccles, Alex Boussioutas, Faye Elliott, Rodney J. Scott, Jem Rashbass, Patrick J. Morrison, Harsh Sheth, Gabriela Möslein, Raj Ramesar, John C. Mathers, Jan Lubinski, Annika Lindblom, Judy W. C. Ho, Eamonn R. Maher

المساهمون: HUS Abdominal Center, Clinicum, II kirurgian klinikka, Helsinki University Hospital Area

المصدر: Burn, J, Sheth, H, Elliott, F, Reed, L, Macrae, F, Mecklin, J P, Möslein, G, McRonald, F E, Bertario, L, Evans, D G, Gerdes, A M, Ho, J W C, Lindblom, A, Morrison, P J, Rashbass, J, Ramesar, R, Seppälä, T, Thomas, H J W, Pylvänäinen, K, Borthwick, G M, Mathers, J C, Bishop, D T, Boussioutas, A, Brewer, C, Cook, J, Eccles, D, Ellis, A, Hodgson, S V, Lubinski, J, Maher, E R, Porteous, M EM, Sampson, J, Scott, R J, Side, L & CAPP2 Investigators 2020, ' Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study : a double-blind, randomised, placebo-controlled trial ', The Lancet, vol. 395, no. 10240, pp. 1855-1863 . https://doi.org/10.1016/S0140-6736(20)30366-4
Evans, D G & et al. 2020, ' Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study : a double-blind, randomised, placebo-controlled trial ', Lancet, vol. 395, no. 10240, pp. 1855-1863 . https://doi.org/10.1016/S0140-6736(20)30366-4

مصطلحات موضوعية: RESISTANT STARCH, Placebo-controlled study, 030204 cardiovascular system & hematology, 0302 clinical medicine, Life Tables, 030212 general & internal medicine, 11 Medical and Health Sciences, media_common, RISK, Aspirin, education.field_of_study, Anti-Inflammatory Agents, Non-Steroidal, LOW-DOSE ASPIRIN, General Medicine, Lynch syndrome, 3. Good health, Intention to Treat Analysis, Anti-Inflammatory Agents, Non-Steroidal/adverse effects, medicine.drug, CHEMOPREVENTION, medicine.medical_specialty, Heterozygote, 3122 Cancers, Population, NEOPLASIA, Aspirin/adverse effects, Placebo, CAPP2 Investigators, Medication Adherence, 03 medical and health sciences, Double-Blind Method, Internal medicine, General & Internal Medicine, Colorectal Neoplasms, Hereditary Nonpolyposis/genetics, BENEFITS, medicine, media_common.cataloged_instance, Humans, European union, education, Proportional Hazards Models, Intention-to-treat analysis, Cancer prevention, business.industry, MORTALITY, 3126 Surgery, anesthesiology, intensive care, radiology, medicine.disease, Colorectal Neoplasms, Hereditary Nonpolyposis, business, Follow-Up Studies

الوصف: BACKGROUND: Lynch syndrome is associated with an increased risk of colorectal cancer and with a broader spectrum of cancers, especially endometrial cancer. In 2011, our group reported long-term cancer outcomes (mean follow-up 55·7 months [SD 31·4]) for participants with Lynch syndrome enrolled into a randomised trial of daily aspirin versus placebo. This report completes the planned 10-year follow-up to allow a longer-term assessment of the effect of taking regular aspirin in this high-risk population.METHODS: In the double-blind, randomised CAPP2 trial, 861 patients from 43 international centres worldwide (707 [82%] from Europe, 112 [13%] from Australasia, 38 [4%] from Africa, and four [FINDINGS: Between January, 1999, and March, 2005, 937 eligible patients with Lynch syndrome, mean age 45 years, commenced treatment, of whom 861 agreed to be randomly assigned to the aspirin group or placebo; 427 (50%) participants received aspirin and 434 (50%) placebo. Participants were followed for a mean of 10 years approximating 8500 person-years. 40 (9%) of 427 participants who received aspirin developed colorectal cancer compared with 58 (13%) of 434 who received placebo. Intention-to-treat Cox proportional hazards analysis revealed a significantly reduced hazard ratio (HR) of 0·65 (95% CI 0·43-0·97; p=0·035) for aspirin versus placebo. Negative binomial regression to account for multiple primary events gave an incidence rate ratio of 0·58 (0·39-0·87; p=0·0085). Per-protocol analyses restricted to 509 who achieved 2 years' intervention gave an HR of 0·56 (0·34-0·91; p=0·019) and an incidence rate ratio of 0·50 (0·31-0·82; p=0·0057). Non-colorectal Lynch syndrome cancers were reported in 36 participants who received aspirin and 36 participants who received placebo. Intention-to-treat and per-protocol analyses showed no effect. For all Lynch syndrome cancers combined, the intention-to-treat analysis did not reach significance but per-protocol analysis showed significantly reduced overall risk for the aspirin group (HR=0·63, 0·43-0·92; p=0·018). Adverse events during the intervention phase between aspirin and placebo groups were similar, and no significant difference in compliance between intervention groups was observed for participants with complete intervention phase data; details reported previously.INTERPRETATION: The case for prevention of colorectal cancer with aspirin in Lynch syndrome is supported by our results.FUNDING: Cancer Research UK, European Union, MRC, NIHR, Bayer Pharma AG, Barbour Foundation.

وصف الملف: application/pdf; text

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b883398de7c0cc7e549ca68d176f77a1
https://curis.ku.dk/portal/da/publications/cancer-prevention-with-aspirin-in-hereditary-colorectal-cancer-lynch-syndrome-10year-followup-and-registrybased-20year-data-in-the-capp2-study(731041a4-aa9f-42c7-b9db-83326e8b4a6d).html

المؤلفون: Xin, Yang, Goska, Leslie, Alicja, Doroszuk, Sandra, Schneider, Jamie, Allen, Brennan, Decker, Alison M, Dunning, James, Redman, James, Scarth, Inga, Plaskocinska, Craig, Luccarini, Mitul, Shah, Karen, Pooley, Leila, Dorling, Andrew, Lee, Muriel A, Adank, Julian, Adlard, Kristiina, Aittomäki, Irene L, Andrulis, Peter, Ang, Julian, Barwell, Jonine L, Bernstein, Kristie, Bobolis, Åke, Borg, Carl, Blomqvist, Kathleen B M, Claes, Patrick, Concannon, Adeline, Cuggia, Julie O, Culver, Francesca, Damiola, Antoine, de Pauw, Orland, Diez, Jill S, Dolinsky, Susan M, Domchek, Christoph, Engel, D Gareth, Evans, Florentia, Fostira, Judy, Garber, Lisa, Golmard, Ellen L, Goode, Stephen B, Gruber, Eric, Hahnen, Christopher, Hake, Tuomas, Heikkinen, Judith E, Hurley, Ramunas, Janavicius, Zdenek, Kleibl, Petra, Kleiblova, Irene, Konstantopoulou, Anders, Kvist, Holly, Laduca, Ann S G, Lee, Fabienne, Lesueur, Eamonn R, Maher, Arto, Mannermaa, Siranoush, Manoukian, Rachel, McFarland, Wendy, McKinnon, Alfons, Meindl, Kelly, Metcalfe, Nur Aishah, Mohd Taib, Jukka, Moilanen, Katherine L, Nathanson, Susan, Neuhausen, Pei Sze, Ng, Tu, Nguyen-Dumont, Sarah M, Nielsen, Florian, Obermair, Kenneth, Offit, Olufunmilayo I, Olopade, Laura, Ottini, Judith, Penkert, Katri, Pylkäs, Paolo, Radice, Susan J, Ramus, Vilius, Rudaitis, Lucy, Side, Rachel, Silva-Smith, Valentina, Silvestri, Anne-Bine, Skytte, Thomas, Slavin, Jana, Soukupova, Carlo, Tondini, Alison H, Trainer, Gary, Unzeitig, Lydia, Usha, Thomas, van Overeem Hansen, James, Whitworth, Marie, Wood, Cheng Har, Yip, Sook-Yee, Yoon, Amal, Yussuf, George, Zogopoulos, David, Goldgar, John L, Hopper, Georgia, Chenevix-Trench, Paul, Pharoah, Sophia H L, George, Judith, Balmaña, Claude, Houdayer, Paul, James, Zaki, El-Haffaf, Hans, Ehrencrona, Marketa, Janatova, Paolo, Peterlongo, Heli, Nevanlinna, Rita, Schmutzler, Soo-Hwang, Teo, Mark, Robson, Tuya, Pal, Fergus, Couch, Jeffrey N, Weitzel, Aaron, Elliott, Melissa, Southey, Robert, Winqvist, Douglas F, Easton, William D, Foulkes, Antonis C, Antoniou, Marc, Tischkowitz

المصدر: J Clin Oncol

مصطلحات موضوعية: Adult, Aged, 80 and over, Male, Ovarian Neoplasms, Risk, Internationality, Age Factors, Middle Aged, Breast Neoplasms, Male, Pancreatic Neoplasms, Neoplasms, RAPID COMMUNICATIONS, Humans, Female, Genetic Predisposition to Disease, Fanconi Anemia Complementation Group N Protein, Germ-Line Mutation, Aged

الوصف: PURPOSE: To estimate age-specific relative and absolute cancer risks of breast cancer and to estimate risks of ovarian, pancreatic, male breast, prostate, and colorectal cancers associated with germline PALB2 pathogenic variants (PVs) because these risks have not been extensively characterized. METHODS: We analyzed data from 524 families with PALB2 PVs from 21 countries. Complex segregation analysis was used to estimate relative risks (RRs; relative to country-specific population incidences) and absolute risks of cancers. The models allowed for residual familial aggregation of breast and ovarian cancer and were adjusted for the family-specific ascertainment schemes. RESULTS: We found associations between PALB2 PVs and risk of female breast cancer (RR, 7.18; 95% CI, 5.82 to 8.85; P = 6.5 × 10(−76)), ovarian cancer (RR, 2.91; 95% CI, 1.40 to 6.04; P = 4.1 × 10(−3)), pancreatic cancer (RR, 2.37; 95% CI, 1.24 to 4.50; P = 8.7 × 10(−3)), and male breast cancer (RR, 7.34; 95% CI, 1.28 to 42.18; P = 2.6 × 10(−2)). There was no evidence for increased risks of prostate or colorectal cancer. The breast cancer RRs declined with age (P for trend = 2.0 × 10(−3)). After adjusting for family ascertainment, breast cancer risk estimates on the basis of multiple case families were similar to the estimates from families ascertained through population-based studies (P for difference = .41). On the basis of the combined data, the estimated risks to age 80 years were 53% (95% CI, 44% to 63%) for female breast cancer, 5% (95% CI, 2% to 10%) for ovarian cancer, 2%-3% (95% CI females, 1% to 4%; 95% CI males, 2% to 5%) for pancreatic cancer, and 1% (95% CI, 0.2% to 5%) for male breast cancer. CONCLUSION: These results confirm PALB2 as a major breast cancer susceptibility gene and establish substantial associations between germline PALB2 PVs and ovarian, pancreatic, and male breast cancers. These findings will facilitate incorporation of PALB2 into risk prediction models and optimize the clinical cancer risk management of PALB2 PV carriers.

URL الوصول: https://explore.openaire.eu/search/publication?articleId=pmid________::cf42d4788d5d2d210088fc88878c6fa8
https://pubmed.ncbi.nlm.nih.gov/31841383